Sihuan Pharma Teams With Biocytogen on AI-Driven Obesity Drug R&D

Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) just unveiled an announcement.

Sihuan Pharmaceutical Holdings Group has entered a strategic collaboration with Biocytogen Pharmaceuticals to accelerate development of innovative drugs, initially focusing on next-generation weight loss therapies. The partnership combines Sihuan’s full-industry-chain capabilities in R&D, large-scale production, and commercialization with Biocytogen’s AI-driven fully human antibody discovery and advanced preclinical platforms.

The first joint project targets obesity with an investigational drug designed to safely enhance energy expenditure while preserving or increasing muscle mass, addressing unmet needs in current weight loss treatments. By leveraging an “AI+High-throughput” model, the collaboration aims to shorten development cycles and reduce costs, potentially strengthening Sihuan’s competitive position in obesity and other high-potential disease areas while aligning with broader industry trends toward AI-enabled drug discovery.

The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.

More about Sihuan Pharmaceutical Holdings Group

Sihuan Pharmaceutical Holdings Group is an international medical aesthetics and pharmaceutical company founded in 2001 and listed in Hong Kong since 2010. The group focuses on innovative drug and medical aesthetic product development, supported by an independent R&D platform, broad global pipeline, cost-efficient multi-dosage manufacturing, and a mature sales network, aiming to become a leading medical aesthetics and biopharmaceutical player in China.

Average Trading Volume: 33,790,877

Technical Sentiment Signal: Buy

Current Market Cap: HK$12.69B

Learn more about 0460 stock on TipRanks’ Stock Analysis page.